Loading stock data…
PTC Therapeutics (PTCT)
$76.82-1.63 (-2.08%)
Market ClosedLast close Jul 24
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PTC Therapeutics, Inc. in the Healthcare sector is trading at $76.82 with a market capitalization of $6.2B. Wall Street consensus targets $96.07 (14 analysts), implying a +25.1% move over the next 12 months. The stock is currently 15% below its 52-week high of $90.87, remaining 5.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $272.55M↑ | $164.68M↓ | $211.01M↑ | $178.88M↓ | $1.18B |
| Gross Profit | $244.52M↑ | $157.73M↓ | $195.23M↑ | $167.46M↓ | $1.16B |
| Operating Income | $45.89M↑ | -$81.62M↓ | $3.49M↑ | -$34.86M↓ | $969.50M |
| Net Income | -$2.81M↑ | -$134.97M↓ | $15.90M↑ | -$64.85M↓ | $866.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
103.47%
Volume
Today's trading volume
803,070
Recent News
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
This insider maintains 63,198 shares across direct and indirect accounts while holding 45,036 derivative securities.
PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data
PTC Therapeutics stock has delivered a 116.6% return over the past three years, yet current valuation checks suggest the shares are no longer an obvious bargain and may be leaning toward the expensive side. For investors, the tension is between that strong track record and a mixed set of signals on how much value is actually priced in today. Over the past three years, PTC Therapeutics has returned 116.6%, which puts extra focus on whether the current share price still leaves enough room for...